Pfizer Plans For COVID Transition And RSV Vaccine Launch
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.
The COVID-19 vaccine and treatment market is expected to evolve into more a flu-like volume and market in 2023, but will remain a "multi-billion dollar" franchise, Bourla said.